Published: May 10, 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE)
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021.
“We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the FDA, which was granted Priority Review, and are on track to file our NDA for AXS-07 for the acute treatment of migraine this quarter,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Pre-commercial activities are intensifying as planned to ensure launch readiness assuming FDA approval. The rest of our pipeline continues to progress with the anticipated initiation of the plann
AXS-07 for migraine, NDA submission (2Q 2021)
AXS-05 for smoking cessation, FDA meeting (3Q 2021)
AXS-05 for MDD, commercial launch, if approved (2H 2021)
Clinical Trial Readouts:
Clinical Trial Initiations:
Upcoming Scientific Conferences
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021
American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021
American Headache Society (AHS) annual meeting, June 3-6, 2021
Upcoming Investor Conferences
BofA Health Care Conference, May 11, 2021 (to be webcast)
RBC Capital Markets Global Healthcare Conference, May 18, 2021 (to be webcast)
UBS Global Healthcare Virtual Conference, May 24, 2021 (to be webcast)
William Blair Growth Stock Conference, June 3, 2021 (to be webcast)
First Quarter 2021 Financial Results
Early puberty in girls may be big bang theory for migraine
By Dr. Osei Boaitey, Institute Of Qualitative Methodology University of Alberta, Canada Listen to article
Adolescent girls who reach puberty at an earlier age may also have a greater chance of developing migraine headaches, according to new research from investigators at the University of Cincinnati (UC) College of Medicine. We know that the percentage of girls and boys who have migraine is pretty much the same until menstruation begins, says Vincent Martin, MD, professor in the Division of General Internal Medicine and director of the Headache and Facial Pain Center at the UC Gardner Neuroscience Institute. When the menstrual period starts in girls, the prevalence goes way up, but what our data suggests is that it occurs even before that.
May 6, 2021
UCLA In the News lists selected mentions of UCLA in the world’s news media. Some articles may require registration or a subscription to view. See more UCLA In the News.
“If something becomes stigmatized, people become reluctant to admit that they’re part of that ‘problem’-causing group so the situation actually becomes exacerbated,” said Dr. Chandra Ford, a professor of community health sciences at UCLA Fielding School of Public Health. Ford recommends trying to make appropriate resources available for your loved ones based on their specific concerns and letting them make their own informed decision.
“It’s really terrific. I think everybody is to be congratulated, both for stepping up and getting vaccinated so we’ve got about 40% of the California population [that] has been vaccinated. Obviously we want to get that higher, but terrific so far. And the fact that people have been still maintaining to doing the public health measures like the physical
martin-dm/Getty Images
Of all the aches and pains I spend my days investigating as a family doctor, none seem to be as anxiety-provoking as a headache. And that s often true, both for patients wondering, Could this be something dangerous? and for clinicians trying to get to the root of pain that can be totally unexplained and yet completely debilitating.
Concerns about headaches in my practice have picked up over the past year as we ve seen them as a symptom in acute COVID-19 infections and among long-haulers and more recently when news broke about the (very, very few) brain clots linked to the Johnson & Johnson vaccine.